Relationship between IgG anti-B2GPI positivity and APS thrombotic clinical manifestations
| First author (y) . | No. of participants . | No. of anti-B2GPI (+) . | Anti-B2GPI positivity cutoff . | No. controls for assay calibration . | Length of follow-up . | Thrombosis . |
|---|---|---|---|---|---|---|
| Forastiero (2005) | 194 patients with persistently positive LA or aCL | 64 IgG (+) 59 IgM (+) | 99th percentile | 95 | Median of 45 mo | Increased risk |
| Wahl (1998) | 71 inpatients admitted for acute VTE | 7 IgG (+) | 3 SD from mean | 20 | Mean 4.9 y | Increased risk |
| First author (y) . | No. of participants . | No. of anti-B2GPI (+) . | Anti-B2GPI positivity cutoff . | No. controls for assay calibration . | Length of follow-up . | Thrombosis . |
|---|---|---|---|---|---|---|
| Forastiero (2005) | 194 patients with persistently positive LA or aCL | 64 IgG (+) 59 IgM (+) | 99th percentile | 95 | Median of 45 mo | Increased risk |
| Wahl (1998) | 71 inpatients admitted for acute VTE | 7 IgG (+) | 3 SD from mean | 20 | Mean 4.9 y | Increased risk |
SD, standard deviation.